The short version of GIP receptor fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-27 and is reviewed periodically as new material appears.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Theodoros "Theo" Angelopoulos (Greek: Θεόδωρος Αγγελόπουλος; 27 April 1935 – 24 January 2012) was a Greek filmmaker, screenwriter and film producer. He dominated the Greek art film industry from 1975 on, and Angelopoulos was one of the most influential and widely respected filmmakers in the world. He started making films in 1967. In the 1970s he made a series of political films about modern Greece. Angelopoulos' films, described by Martin Scorsese as those of "a masterful filmmaker", are characterized by slight movement and distance changes, long takes, and complex, carefully composed scenes. His cinematic method is often described as "sweeping" and "hypnotic." Angelopoulos has said that in his shots, “time becomes space and space becomes time.” The pauses between action or music are important to creating the total effect. In 1998 his film Eternity and a Day went on to win the Palme d'Or at the 51st edition of the Cannes Film Festival, and his films have been shown at many of the world's esteemed film festivals.
The newer restaurant concepts did not perform as well as they had hoped, so ShopHouse Southeast Asian Kitchen and Tasty Made were closed in March 2017 and February 2018 respectively, leaving only Pizzeria Locale operating besides the parent company. In February 2023, Chipotle opened their first Farmesa Fresh Eatery in Santa Monica, California, serving bowls containing customers' choice of a protein, a green or grain, two sides, a topping, and a selection of up to five sauces. Some of the choices included steak, salmon, whipped potatoes, sweet potato chips, beets, and cauliflower. In July 2023, Chipotle exited the highly competitive pizza restaurant industry by announcing that they were closing all of their remaining Pizzeria Locale locations and would "dissolve the business". Chipotle also abandoned Farmesa in April 2024.
Normorphine is an opiate analogue, the N-demethylated derivative of morphine, that was first described in the 1950s when a large group of N-substituted morphine analogues were characterized for activity. The compound has relatively little opioid activity in its own right, but is a useful intermediate which can be used to produce both opioid antagonists such as nalorphine, and also potent opioid agonists such as N-phenethylnormorphine. with its formation from morphine catalyzed by the liver enzymes CYP3A4 and CYP2C8. Normorphine is a controlled substance listed under the Single Convention On Narcotic Drugs 1961 and the laws in various states implementing it; for example, in the United States it is a Schedule I Narcotic controlled substance, with an ACSCN of 9313 and an annual aggregate manufacturing quota of 18 grams in 2014, unchanged from the prior year. The salts in use are the free base hexahydrate (free base conversion ratio 0.715), and hydrochloride (0.833).
Vice writer Patrick Klepek felt that the Headcrab was an iconic enemy known by people outside the Half-Life fandom, stating that due to it becoming more familiar, it became less intimidating, citing the fact that it was made into a plush. He felt that the Headcrabs in Half-Life: Alyx were responsible for making Headcrabs scary again, stating that it being a virtual reality game made its attacks that much more frightening. He felt that the Headcrabs being scary served as proof of how well Alyx works as a video game. Dread Central writer Justin Wood felt similarly about the virtual reality technology, stating that the sight of Headcrabs jumping at the player created "visceral reactions", as well as making him uncomfortable to hear them creeping around. Kotaku writer Nathan Grayson stated that, through his time playing Alyx, he had never gotten used to the "nauseating sense of dread" from the fear of being attacked by Headcrabs. He felt that this went beyond just being in virtual reality, praising the development team for managing to create such good sound design and animation that being accosted by Headcrabs inspired genuine fear in him. Twitch producer Mary Kish regarded Alyx as one of her favorite video games of 2020, stating that it being "genuinely scary" was a large part of why she liked it. She discussed how the Headcrabs function in it, which caused her to hold her breath in response to a Headcrab's presence, believing they pulled off a sense of danger well.
==== Intracrine VEGF and cardiac protection ==== The intracrine actions of VEGF have been implicated in cardioprotection, particularly in response to ischemic stress. Cardiac myocytes exposed to hypoxic conditions exhibit increased intracellular VEGF, which appears to play a role in cellular adaptation to oxygen deprivation. This intracrine mechanism promotes the expression of stress-response genes, enhances mitochondrial function, and modulates intracellular calcium signaling, which is critical for maintaining contractility under stress conditions. VEGF has been shown to interact with intracellular angiogenin, another intracrine involved in endothelial cell survival. This interaction establishes a feedback loop where VEGF upregulates angiogenin, which, in turn, enhances VEGF expression. This loop suggests that intracrine VEGF may be a crucial component in the regulation of myocardial vascularization and repair.
Sources: en.wikipedia.org
Bangladesh Council of Scientific and Industrial Research (BCSIR) (Bengali: বাংলাদেশ বিজ্ঞান ও শিল্প গবেষণা পরিষদ) is a scientific research organization and regulatory body of Bangladesh. Its main objective is to pursue scientific research for the betterment of the Bangladeshi people. It was established on 16 November 1973.
== Occurrence == Pyrite is the most common of sulfide minerals and is widespread in igneous, metamorphic, and sedimentary rocks. It is a common accessory mineral in igneous rocks, where it also occasionally occurs as larger masses arising from an immiscible sulfide phase in the original magma. It is found in metamorphic rocks as a product of contact metamorphism. It also forms as a high-temperature hydrothermal mineral, though it occasionally forms at lower temperatures. Pyrite occurs both as a primary mineral, present in the original sediments, and as a secondary mineral, deposited during diagenesis. Pyrite and marcasite commonly occur as replacement pseudomorphs after fossils in black shale and other sedimentary rocks formed under reducing environmental conditions. Pyrite is common as an accessory mineral in shale, where it is formed by precipitation from anoxic seawater, and coal beds often contain significant pyrite. Notable deposits are found as lenticular masses in Virginia, U.S., and in smaller quantities in many other locations. Large deposits are mined at Rio Tinto in Spain and elsewhere in the Iberian Peninsula.
Spain also made history by being the first nation to become the reigning champion for both the men's and women's World Cups, and the first team to win the World Cup while conceding only one goal during the tournament. France captain Kylian Mbappé won his second consecutive Golden Boot for scoring the most goals (10) during the tournament. He became the all-time leading goalscorer at the World Cup and the first player to win multiple World Cup Golden Boots. The average number of goals per match in the tournament was 2.96, the highest since the 1970 edition. Spain captain Rodri won the Golden Ball as the best player of the tournament. Unai Simón won the Golden Glove as the tournament's best goalkeeper, while Pau Cubarsí won the Young Player Award as the tournament's best young player. Nearly 7 million people attended matches during the tournament, surpassing the 1994 edition to set a new record for the highest attendance in World Cup history. The 2026 World Cup reportedly generated a record $15 billion in revenue.
=== Functional analogues and derivatives === 3,3-Difluoroalanine: Difluorinated alanine with similar residue hydrophobicity to that of isoleucine. 3,3,3-Trifluoroalanine: Trifluorinated alanine that expresses properties of a suicide inhibitor for alanine racemases. 3,3,3-Trifluoroalanine N-carboxyanhydride: A cyclic anhydride of trifluorinated alanine investigated for use as a monomer in homo- and co-polymerisations.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.